Reviva Pharmaceuticals Q1 2023 Earnings Report

Reviva Pharmaceuticals EPS Results

• Actual EPS: -$0.30
• Consensus EPS: -$0.36
• Beat/Miss: Beat by +$0.06
• One Year Ago EPS: N/A

Reviva Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Reviva Pharmaceuticals Announcement Details

• Quarter: Q1 2023
• Date: 5/15/2023
• Time: N/A

Reviva Pharmaceuticals (NASDAQ:RVPH), a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.